Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals

Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.

Rejection
Dr Reddy’s Has Received A Pushback On Two US Applications • Source: Shutterstock

Dr. Reddy's has received a complete response letter from the US Food and Drug Administration over the Indian firm’s US application for a generic version of

Merck Sharp & Dohme's NuvaRing (etonogestrel/ethinylestradiol) vaginal ring contraceptive brand.

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.